Executive Summary
HHS allocated $110M across three long-term contracts (to 2026-2027) supporting organ procurement infrastructure ($53M to nonprofit UNOS), CMS data analytics ($30M to Newwave), and antibiotic R&D ($27M to small business Revagenix), with $64M already outlaid signaling execution momentum. Revagenix's cost-plus funding through Phase 1 is the standout bullish signal for biotech innovation amid antimicrobial resistance trends. Neutral signals dominate for stable services, but unexercised options (~$8M) and extensions offer upside; limited direct public equity exposure as recipients are nonprofit/private.
Tracking the trend? Catch up on the prior All HHS Contracts digest from December 26, 2025.
Investment Signals(2)
- $27M non-dilutive R&D funding accelerates antibiotic pipeline(HIGH)▲
Revagenix secured $26.9M obligation ($20.5M outlaid) for IND-to-Phase 1 development through 2026, providing critical runway for small biotech.
- Stable multi-year funding for transplant and data infrastructure(HIGH)▲
$83M obligated to UNOS and Newwave underscores reliable federal support for essential HHS services through 2027.
Risk Flags(2)
- Execution[MEDIUM RISK]▼
Long performance periods (to 2026-2027) with $46M un-outlayed expose to delays, cost overruns in fixed-price (Newwave) or cost-sharing (UNOS) structures.
- Regulatory[HIGH RISK]▼
R&D milestone risks in Revagenix (Phase 1 success) and potential renewal uncertainties for all contracts post-2026.
Opportunities(2)
- ◆
$8M unexercised options across contracts could boost total value to $393M if fully exercised.
- ◆
Federal push into antibiotic R&D signals broader non-dilutive funding wave for antimicrobial resistance solutions.
Sector Themes(2)
- ◆
$83M to organ procurement and CMS analytics reflects priority on core healthcare operations via nonprofits and IT firms.
- ◆
$27M to Revagenix highlights targeted antibiotic innovation investment amid global resistance concerns.
Watch List(3)
- 👁
{"entity"=>"Revagenix Inc", "reason"=>"$27M funding with $6.9M options; Phase 1 progress key to follow-ons.", "trigger"=>"IND filing or Phase 1 initiation (by 2026)"}
- 👁
{"entity"=>"UNOS Organ Procurement Network", "reason"=>"$53M obligation with $275M potential options; renewal to 2026 critical.", "trigger"=>"Option exercises or extension award"}
- 👁
{"entity"=>"Newwave CDAT Delivery Order", "reason"=>"$11M un-outlayed; 2027 extension possible.", "trigger"=>"Outlay acceleration >$2M/quarter"}
Get daily alerts with 2 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC